Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
about
Heparin-induced thrombocytopenia in the ICU: an overviewUnfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patientsHITlights: a career perspective on heparin-induced thrombocytopeniaAtomic description of the immune complex involved in heparin-induced thrombocytopeniaA multistate model for bivariate interval-censored failure time data.Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment.The management of heparin-induced thrombocytopenia.Beyond heparin and warfarin: the new generation of anticoagulants.Heparin-induced thrombocytopenia: treatment options and special considerations.Testing for heparin-induced thrombocytopenia: are we there yet?Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?Determinants of PF4/heparin immunogenicitySuccessful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case seriesThe use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushesCurrent concepts review: heparin-induced thrombocytopenia.Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacementFondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis.Fondaparinux: does it cause HIT? Can it treat HIT?IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approachHIT paradigms and paradoxes.Immunogenic but effective: the HIT-fondaparinux brain puzzler.Fondaparinux-associated heparin-induced thrombocytopeniaParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesDisruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)Management of heparin-induced thrombocytopenia.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE).Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital.Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis.Heparin-induced thrombocytopenia following hip and knee arthroplasty.Heparin-induced thrombocytopenia leading to stroke, lower extremity arterial occlusive disease, and skin necrosis: a case report.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Efficacy and safety of off-label use of fondaparinux in the management of heparin-induced thrombocytopenia with thrombosis in an elderly woman.
P2860
Q21194907-85935F40-0E54-4BB6-8DD2-43CD7E20C178Q24200589-51A6E5E0-1145-405E-B097-82699F8E3F50Q26828351-F2A3E540-2EA6-4FEC-A7A6-BD26A4F2FAD9Q30665349-25D95CAD-6FE3-4D2B-9B1E-CFA5D01FE582Q31143773-5F6E5465-1C2F-4701-9C43-AB3BEDFAB2C7Q33370473-407004E4-2AF6-432B-A685-CABDA52AE53EQ33371013-FE29786B-7C48-4EC0-80F0-E9EDCCC2F098Q33374258-BBADD9C3-8B20-43DD-90F0-90B8AE2166A6Q33374658-2A9A3012-1A19-45CC-868B-01BCFF2E9AD2Q33374916-79DA97F1-801E-49A7-981E-34DAE5F27A0CQ33376013-F31D0728-1801-4B89-AAEF-470B2E172ACFQ33376629-04410F2E-EF88-4AB3-9648-A6BA342780D1Q33380179-65039339-9010-4592-86CF-7666E74CA248Q33381352-FF4C612D-1511-4C90-AC95-898E712F5F28Q33382108-25400FF8-6A25-4C7F-A9C3-666F149E5BC3Q33384243-1EEE127D-738F-4947-84EB-A5A8FD29F5CBQ33386621-CBB355DA-9B6A-40A8-8D32-E731FA818313Q33387713-A711CD07-2145-45C5-8A8A-20CEE6397A03Q33389966-52284517-3312-435B-9E36-4794484DE191Q33392854-F7284914-7A97-400E-BAD9-235FA9610A45Q33392864-FEB4E365-EF54-4457-B726-2754D40C114CQ33393788-66EBE1F8-778E-49A4-8158-94978F00DCCDQ33394988-C02C5130-5519-4565-AE8C-5D7FDBFE1FC2Q33396243-F17829E6-314C-4CF3-96A8-2022DCBDA8F2Q33396313-F291B87E-D86D-4478-BA75-9F608AD7EC34Q33397282-82E70E0C-632D-4DFE-B2A0-C11D8F0EFAAFQ33399335-96134591-37CA-4503-8763-A58DABC341D2Q33399576-3C37050E-F9CF-48F2-8B6D-A09681665E5DQ33399613-3E2020D3-7FA5-403F-8828-76A2FC7F386CQ33400573-DD0149D2-3BE7-4F0A-990E-89914E12B5B9Q33401236-CC7E3FEF-74A0-46B1-A315-A2D4886BBF3AQ33402370-3F3B6D1D-BF0D-4E17-95C0-F67E8089EE7BQ33403703-FDC59E0E-87E1-46AE-865B-30E376A64C7BQ33404467-7B4ADBCB-5148-45CF-98CD-64E14918F5A6Q33404709-406BB92F-70F7-40B7-A120-1E79738DD843Q33405846-575AB233-1AC3-4868-BBE4-25874877D602Q33406618-6CBDD7E7-CA60-4B5B-AD1A-0F5F6FCE61C7Q33406904-096D8B74-5B8D-448C-9432-4E6AB510292EQ33407198-B5899916-E092-49B5-93DF-814EE3C3449FQ33408949-65D5EB5A-12B5-453E-A3BD-4D3226BEB42B
P2860
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@ast
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@en
type
label
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@ast
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@en
prefLabel
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@ast
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@en
P2093
P2860
P1433
P1476
Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin
@en
P2093
Bengt I Eriksson
Jane C Moore
Jo-Ann I Sheppard
John G Kelton
Richard J Cook
Victor J Marder
P2860
P304
P356
10.1182/BLOOD-2005-05-1938
P407
P577
2005-08-18T00:00:00Z